CRISPR/Cas9 Genome Editing for Human Melanoma Model Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating human cancer models are limited in their ability to introduce precise genetic alterations in human cells, particularly in differentiated cells like melanocytes, and struggle to replicate the complex genetic landscape of human melanoma, leading to conflicting results and an inability to accurately model the phenotypic contributions of specific mutations.
Innovation Solution
A method involving genome editing using CRISPR/Cas9 to introduce defined mutations such as CDKN2A, BRAF, TERT, PTEN, and TP53 mutations into primary human melanocytes, allowing for the sequential selection and propagation of mutations that mimic the genetic alterations found in human melanomas, enabling the study of cancer development and drug screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If sub-cloning is used to achieve clonal population, then genetic uniformity is improved, but cell artifacts are generated and model reliability deteriorates
Solution Approach 1:
The patent applies preliminary action by performing bulk genome editing on the entire cell population before any clonal separation occurs. Multiple guide RNAs targeting the same gene locus are introduced simultaneously, enabling all cells to undergo the desired genetic modification in a unified manner. This approach establishes genetic uniformity through synchronized editing rather than through post-editing clonal selection, thereby avoiding the artifacts associated with sub-cloning while maintaining model reliability.
2Manufacturing precision
If multiple genetic alterations are introduced, then cancer model accuracy is improved, but experimental complexity increases
Solution Approach 1:
The patent merges multiple genetic modification operations into a single unified experiment by introducing multiple guide RNAs targeting different genes simultaneously. This allows multiple cancer-relevant genetic alterations to be introduced in one bulk editing event rather than requiring separate experiments for each gene, thereby improving cancer model accuracy while reducing experimental complexity through consolidation.
Solution Approach 2:
The patent employs a universal bulk genome editing platform that can simultaneously target multiple genes across different biological pathways. The system uses a common delivery mechanism and selection strategy that works regardless of which specific genes are being modified, enabling flexible introduction of various genetic alterations (such as BRAF V600E, NRAS Q61R, TP53 R175H) without requiring pathway-specific experimental designs.
3Reliability
If genome editing is performed in differentiated cells, then model physiological relevance is improved, but editing efficiency decreases
Solution Approach 1:
The patent overcomes the reduced editing efficiency in differentiated cells by optimizing key parameters of the genome editing system. This includes using highly active Cas9 variants, optimizing guide RNA design for maximum binding affinity, adjusting electroporation conditions to enhance delivery efficiency, and implementing strong positive selection pressure with puromycin resistance markers. These parameter optimizations enable effective genome editing in primary human melanocytes and other differentiated cells, achieving physiological relevance without sacrificing productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the creation of reliable human cancer models that accurately replicate the genetic and phenotypic characteristics of melanoma, enabling the study of cancer development and drug screening, with mutations being selectively introduced and propagated to high frequencies within cell populations, facilitating the investigation of cancer progression and treatment resistance.
Implementation Method 1
A method involving genome editing using CRISPR/Cas9 to introduce defined mutations such as CDKN2A, BRAF, TERT, PTEN, and TP53 mutations into primary human melanocytes
Implementation Method 2
introducing one or more mutations into one or more cells in a population of cells and culturing the cells until the mutation(s) are positively selected in the population
Data Source
AI summary
The present invention provides methods for introducing mutations to primary cells and selecting for the mutations to obtain a population of cells for modeling cancer. Such methods may comprise at least one round of introducing one or more mutations into one or more cells in a population of cells in vitro and culturing the cells until the mutation(s) are positively selected in the population. The cells may be cultured in vitro. The cells may be cultured in vivo. In certain embodiments, the cells are positively selected in vivo in order to select for cells capable of evading the immune system. In certain embodiments, cells are selected in an immune competent animal model. The cells may primary cells. The population of cells may be used for drug screening and for studying cancer.